Obesity due to disruption of MC4R pathway
Methodology & AI Transparency ⓘ
Obesity due to disruption of MC4R pathway Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Obesity due to disruption of MC4R pathway uses ICD-10 E88.82 across Weight & Metabolism specialty care.
- 3 Typical cash cost range: Workup highlights for Obesity due to disruption of MC4R pathway (E88.82): hepatic steatosis screening in Obesity due to disruption of MC4R pathway (E88.82: (FIB-4)).
- 4 Top reported side effects / signs: Longitudinal Obesity due to disruption of MC4R pathway monitoring tracks DEXA Visceral Adipose in Obesity due to disruption of MC4R pathway (E88.82: Tissue (VAT)) toward < 1.0 lb (< 100 cm2) (E88.82).
Ask our AI Specialists anything about Obesity due to disruption of MC4R pathway
What Is Obesity due to disruption of MC4R pathway?
Recognized across U.S. clinical coding as E88.82 (Weight & Metabolism), Obesity due to disruption of MC4R pathway is evaluated via hepatic steatosis screening in Obesity due to disruption of MC4R pathway (E88.82: (FIB-4)) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Obesity due to disruption of MC4R pathway (E88.82) center on pro-inflammatory adipokine signaling in Obesity due to disruption of MC4R pathway (E88.82: (IL-6). targeted weight & metabolism interventions aim to normalize DEXA Visceral Adipose in Obesity due to disruption of MC4R pathway (E88.82: Tissue (VAT)).
Common Symptoms & Clinical Signs
- • Presentation of Obesity due to disruption of MC4R pathway (E88.82): co-existing blood pressure, in Obesity due to disruption of MC4R pathway (E88.82: triglyceride, or fasting)
- • Secondary Obesity due to disruption of MC4R pathway clinical sign: joint load discomfort in Obesity due to disruption of MC4R pathway (E88.82: in knees, hips,)
- • Symptom flares in Obesity due to disruption of MC4R pathway correlating with DEXA Visceral Adipose in Obesity due to disruption of MC4R pathway (E88.82: Tissue (VAT)) deviation outside < 1.0 lb (< 100 cm2) (E88.82)
- • Functional weight & metabolism impact requiring hepatic steatosis screening in Obesity due to disruption of MC4R pathway (E88.82: (FIB-4)) evaluation (E88.82)
Obesity due to disruption of MC4R pathway Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.82 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Obesity due to disruption of MC4R pathway (E88.82: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E88.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Obesity due to disruption of MC4R pathway E88.82] | < 0.50 (E88.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Obesity due to disruption of MC4R pathway (E88.82: Index) | < 1.4 (E88.82) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Obesity due to disruption of MC4R pathway
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Enjaymo (Sutimlimab-Jome) Enjaymo • RxCUI 2591425 | Classical Complement Pathway Inhibitor | 82% | $0.6800 | $ 57.46 /mo |
| Vismodegib Erivedge • RxCUI RXN-50242140-2939 | Hedgehog Pathway Inhibitor | 74% | $0.8600 | $ 43.33 /mo |
| Erivedge (Vismodegib) Erivedge • RxCUI RXN-B50242140 | Hedgehog Pathway Inhibitor | 84% | $1.5100 | $ 117.22 /mo |
| Glasdegib Daurismo • RxCUI RXN-00690298-2736 | Hedgehog Pathway Inhibitor | 84% | $0.9400 | $ 46.57 /mo |
| Sutimlimab-Jome Enjaymo • RxCUI 2591419 | Classical Complement Pathway Inhibitor | 83% | $0.4200 | $ 25.51 /mo |
| Odomzo (Sonidegib) Odomzo • RxCUI 1659927 | Hedgehog Pathway Inhibitor | 93% | $0.4300 | $ 39.46 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Obesity due to disruption of MC4R pathway)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Potent incretin-based therapy for: What a 5,140-Participant Study Found The side effects related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2024-05-15 • Meta-Analysis | N = 5,140 | 99/100 | PMID 38463003 ↗ |
| New Insights on Tirzepatide as a novel effective and safe strategy for treating: What a 11,758-Participant Study Found Tirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Frontiers in public health • 2024-01-15 • Meta-Analysis | N = 11,758 | 99/100 | PMID 38356942 ↗ |
| New Insights on Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the: What a 12,300-Participant Study Found GLP-1RAs triggered more gastrointestinal side effects than placebo, with no in-between difference. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2023-03-15 • Meta-Analysis | N = 12,300 | 99/100 | PMID 36579723 ↗ |
| New Insights on Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the: What a 1,145-Participant Study Found In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation. JACC. Heart failure • 2025-11-15 • Randomized Controlled Trial | N = 1,145 | 96/100 | PMID 41045908 ↗ |
| New Insights on Coadministered Cagrilintide and Semaglutide in Adults with Overweight or: What a 3,417-Participant Study Found Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo. The New England journal of medicine • 2025-08-14 • Phase III Randomized Trial | N = 3,417 | 96/100 | PMID 40544433 ↗ |
Obesity due to disruption of MC4R pathway Patient Community & “People Like Me” Threads
Filter Obesity due to disruption of MC4R pathway community threads and patient logs by age, biological sex, dosage, and treatment duration.